Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

LOS ANGELES--(BUSINESS WIRE)--Jun 9, 2025--
Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen ®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality.
The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally ( GeneReviews ), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression.
Dr. Koshizaka noted, 'We hope our work will accelerate studies on not only WS but also other premature aging disorders and common age-related diseases—ultimately helping to extend health span and improve quality of life in both patients and the broader population.'
Developing NAD+ Therapies for Rare, Age-Related Diseases
This study builds on the growing body of clinical research demonstrating Niagen's potential in rare, age-related diseases (see Table 1 below). In Ataxia Telangiectasia (AT), Niagen has shown improvements in neurological function, coordination, and immune markers, including in pediatric populations.
Rob Fried, CEO of Niagen Bioscience, stated, 'Rare disease research is a priority for Niagen Bioscience, particularly those indications associated with accelerated aging, mitochondrial dysfunction, or NAD+ deficiency.'
The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to NR for the treatment of AT. These designations underscore the urgent unmet need and potential therapeutic value of Niagen in rare disease populations.
Vilhelm Bohr, M.D., Ph.D., D.Sc., former National Institute on Aging (NIA) Chief of the Laboratory of Molecular Genetics, and current Affiliate Professor in Genome Instability and Neurodegeneration at the University of Copenhagen and Scientific Advisor to Niagen Bioscience and coauthor on the study, commented, 'Werner syndrome is a rare genetic disorder that has long served as a valuable model for understanding the mechanisms of human aging. This study marks the first clinical trial using Niagen in those with Werner syndrome, and the findings—particularly improvements in cardiovascular markers—are promising. As Werner syndrome is a well-established model for normal aging, these results also suggest that NAD+ supplementation may support healthier aging in the broader population.'
Study Highlights
This 52-week randomized, double-blind, placebo-controlled crossover trial evaluated the safety and efficacy of oral Niagen supplementation in individuals with WS. The study randomized nine individuals (mean age: 47) who received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks.
Key findings include:
This study represents the first clinical evaluation of Niagen in WS and supports further investigation of NAD+ augmentation as a therapeutic strategy in rare progeroid diseases.
For additional information on the science supporting Niagen ®, visit www.niagenbioscience.com.
About Niagen Bioscience:
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.
At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available.
Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.
Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Xx Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250609224907/en/
CONTACT: Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
[email protected] Bioscience Investor Relations Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
Stephanie Carrington
(646) 277-1282
[email protected]
KEYWORD: NORTH AMERICA UNITED STATES ASIA PACIFIC EUROPE JAPAN CALIFORNIA
INDUSTRY KEYWORD: RESEARCH VITAMINS/SUPPLEMENTS GENETICS CLINICAL TRIALS BIOTECHNOLOGY ALTERNATIVE MEDICINE HEALTH PHARMACEUTICAL SCIENCE
SOURCE: Niagen Bioscience, Inc
Copyright Business Wire 2025.
PUB: 06/09/2025 08:32 AM/DISC: 06/09/2025 08:31 AM
http://www.businesswire.com/news/home/20250609224907/en

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

26 minutes ago

• Yahoo

RFK Jr. dismissing experts creates deadly vaccine hesitancy

Since 1964, pediatricians have looked to the Advisory Committee on Immunization Practices to provide evidence-based recommendations regarding childhood vaccines. We represent more than 80 years of experience as pediatricians in Nashville and have benefitted from ACIP throughout our careers. On June 9, our clinic days were disrupted by the news that Health and Human Services Secretary Robert F. Kennedy Jr. had dismissed all 17 ACIP members. These members are academic clinicians, epidemiologists, immunologists and infectious disease experts. Their service was driven not by money or fame, but by a commitment to the collective health of Americans. ACIP meetings were transparent, being broadcast live and then archived on YouTube, while agendas were posted well in advance of each meeting. The public could request to ask questions at meetings as well as review slide decks that were presented. Kennedy's implication that he was reconstructing the committee to prevent conflicts of interest is far from the truth. In order to preserve objectivity and limit corporate influence on their recommendations, ACIP members already disclose any potential conflict of interest in advance. If a member has a potential conflict, they are not permitted to participate in vaccine discussions, or to vote on that vaccine or any vaccine that a company might bring before ACIP – even if that member didn't work on that specific vaccine. Opinion: As a doctor, I know it will take more than dietary changes to Make America Healthy Again Kennedy also implied that ACIP only ever adds vaccines to the schedule, acting as a rubber stamp for industry. But ACIP recommendations came after analyzing evidence and weighing the benefits and risks. The 1972 decision to stop vaccinating for smallpox was a significant and very well-informed move, reflecting an in-depth understanding of both the science and the broader public health context. Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store. The 2016 recommendation to reduce the number of doses for the HPV vaccine also shows that ACIP actively engaged in fine-tuning vaccination schedules based on the latest research, rather than to increase industry profits. It's crucial for these bodies to make decisions based on science, not external pressures or adherence to a certain ideology. As pediatricians, we have seen patients die from vaccine-preventable diseases. Our pediatric forefathers cared for children in iron lungs due to paralytic polio. Opinion: Please stop letting RFK Jr. make vaccine policies. His new COVID plan is deadly. Kennedy has planted the seeds of the anti-vaccination movement for more than two decades, despite evidence that contradicts his falsehoods. Due to the vaccine hesitancy and refusal he promotes, we are once again seeing more children succumb to vaccine-preventable diseases in America. So far in 2025, we have had pediatric deaths from measles and whooping cough, not to mention more than 200 deaths from influenza. Those numbers will only escalate in the future. Kennedy's decision to eliminate trustworthy members of the ACIP fundamentally changes the nature of this committee. Institutional memory and the trust of physicians were obliterated in one fell swoop. We hold little hope that HHS can put a new trusted committee together in time for the next scheduled ACIP meeting Jun 25-26, given Kennedy's preference for conspiracy theorists and other unqualified people. Through our careers as community pediatricians, we have been blessed by the opportunity to partner with wonderful families who desire what is best for their children. We fervently hope this relationship will be the most important factor when families make decisions regarding vaccinating their children. We call on our elected officials to reinstate the ACIP members Kennedy dismissed and to empower them to continue their work to limit damage from infectious diseases. Doing so will actually help make Americans healthier. James Keffer, MD; Chetan R Mukundan, MD; Jill Obremsky, MD; Elizabeth Triggs, MD; and David Wyckoff, MD, are local pediatricians practicing in different settings around Nashville. This column originally appeared in The Tennessean. You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter. This article originally appeared on Nashville Tennessean: Kennedy's vaccine rhetoric puts children's health at risk | Opinion

Yahoo

27 minutes ago

• Yahoo

Medicare go-broke date pushed up three years in latest trustees report

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. A key trust fund underpinning Medicare's hospital benefit will go broke three years earlier than previously expected absent congressional action, threatening benefits for seniors, according to the Medicare trustees' annual report released Wednesday. The Medicare Hospital Insurance trust fund will be depleted in 2033, instead of 2036, as Medicare spending continues to outpace the program's income, the trustees — a group comprised of the HHS, Treasury and Labor secretaries, along with the Social Security commissioner — warned. The bleaker outlook is due to higher-than-expected spending for hospital care, hospice services and physician-administered drugs. The trustees called on Congress to act quickly to stabilize Medicare, though near-term action is unlikely as the Republican majority focuses on advancing their reconciliation megabill. Medicare has been teetering on the edge of insolvency for a while. But the latest report from Medicare's trustees is more dire than last year's, which projected Medicare would become insolvent in more than a decade. Now, Medicare's hospital trust fund will start running out of money in eight years — when today's 57-year-olds first become eligible for the program. The looming go-broke date is a result of the fund's substantial shortfall as Medicare costs continue to grow rapidly, trustees said in the report. Medicare costs are expected to increase from 3.8% of the gross domestic product in 2024 to 6.2% in 2050 before reaching 6.7% in 2099, the report projects. Costs to another fund that pays Parts B and D, called the Supplemental Medical Insurance trust fund, are also climbing, increasing pressure on beneficiary budgets and the federal budget. (Though, the Supplemental Medical Insurance trust fund is largely funded by premiums and general revenue that resets each year and doesn't face the same solvency concerns.) This year's estimates, which are based on current payment rates, could be conservative, trustees said. Under an alternate scenario, in which provider payments grow at a rate more consistent with underlying medical costs — a change aggressively lobbied for by physician associations — Medicare spending will rise to 8.8% of the GDP in 2099 rather than 6.7%, according to the report. The precarious footing of the federal insurance program, which covers almost 69 million people in the U.S., is due to the country's underlying demographic shifts, according to experts. More and more Americans are aging into Medicare, while at the same time the number of workers paying into its trust fund is dropping. More seniors are also selecting privatized Medicare Advantage plans, which are more expensive than traditional Medicare coverage. If and when the U.S. hits Medicare's go-broke date, the hospital trust fund, which pays hospitals and providers of post-acute services and also covers some of the cost of private Medicare Advantage plans, will have inadequate income to fund those benefits. Medicare payments would immediately be cut by 11%, according to the report. Those cuts would grow over time, likely disrupting services for seniors and reimbursement for providers. It's worth nothing that there's a significant degree of uncertainty in trustees' projections, which vary based on macroeconomic forces in a given year. For example, in 2020, in the early throes of COVID-19, the board predicted the hospital trust fund would run out by 2026. That deadline was pushed back to 2028 and then 2031 in subsequent years' reports, amid a broader economic rebound and more care shifting to cheaper outpatient settings. Still, the fund hasn't met the trustees' test for short-range financial adequacy since 2003, and has triggered funding warnings since 2018. To date, Congress has not allowed Medicare to go under. But legislators' lack of action despite years of warnings is a source of heartburn for budget hawks, Medicare advocates and physician lobbies. Experts say lawmakers need to act soon given many reforms to stabilize Medicare could take a few years to go into effect. 'The projections in this report show that change is needed to address Medicare's financial challenges,' the Medicare trustees wrote in their report. 'The sooner solutions are enacted, the more flexible and gradual they can be.' According to the Committee for a Responsible Federal Budget, restoring Medicare solvency would require Congress to boost the payroll tax rate by 14% or reduce Medicare spending by 9% — both politically unappetizing proposals. Other reforms that could curb Medicare spending, like implementing site-neutral payments or reducing overpayments in MA, have more bipartisan support but aren't a policy priority on the Hill. Republicans are currently focused on hammering out legislation to extend tax cuts from President Donald Trump's first term, cut green energy programs, fund border control and curb Medicaid spending. 'We are running out of time to phase in changes gradually and avoid harsh cuts, sharp tax increases, or unacceptable borrowing. Demagoguing this issue may be politically expedient, but it will ultimately prove ruinous for the tens of millions of Americans that rely on the programs,' Maya MacGuineas, the president of the CRFB, said in a statement Wednesday. Recommended Reading Medicare go-broke date extended to 2036, but warning bells continue ringing

Yahoo

33 minutes ago

• Yahoo

Lifelong Friends Move in Together. But Then Pal's Disrespectful Behavior Threatens to End Friendship

Two lifelong friends moved in together, but it quickly turned disastrous One of the women often disregards her roommate's boundaries, causing tension between the two Now, they wonder if they can salvage their friendshipLiving with a friend can be challenging, especially when boundaries are crossed. A 25-year-old woman seeks support from the Reddit community after ongoing tensions with her best friend and housemate have made their living situation increasingly difficult. The two have been close for decades and were initially excited to live together. However, over time, their differing needs and disregard for each other's wishes have led to tension. Now, the poster has come to realize that their lifestyles have become incompatible. 'I have always known I am pretty introverted and came from not a great family home, so shared with her ahead of time that I will need alone time and there may be days when I'm just chilling solo in my room,' the woman writes in the since-deleted post. Her housemate, on the other hand, turned out to be far more extroverted than she had realized before moving in. This fundamental difference has contributed to growing friction, along with her friend's disregard for boundaries. The woman describes how, while she was out of town, her housemate damaged their shared car but failed to inform her. 'She had some kind of minor accident leaving noticeable scratches on my wing mirror and didn't tell me, leaving me to have to ask about them when I found them,' the woman writes. Beyond property concerns, her housemate often makes unsolicited comments about the poster's health, despite being asked to stop. This is particularly sensitive given the Redditor's history with Polycystic Ovary Syndrome (PCOS) and a past eating disorder. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. 'She will often comment on my diet and make comments about my exercise even when I ask her not to as my health is a difficult journey for me and diet in particular triggers my past binge eating disorder from my crappy home life," she writes. Her housemate has also been allowing people, including strangers, to stay in their shared space without permission. When confronted about this, she failed to respect the woman's wishes for future instances. The final straw came when the woman walked into their living room and found her housemate and her boyfriend being intimate with the door open. 'I just think she should be more considerate and I don't think I want someone in my life who doesn't care about me or how their actions would make me feel,' she writes. Though they have discussed many of these issues after the fact, the woman notes that nothing has changed. Now, as she prepares to move out, she is left wondering whether their friendship can—or should— survive beyond their time as housemates. Read the original article on People